SCHEMBL25544355

SCHEMBL25544355

Cc1cc(-c2c(C3=CCOCC3)cnc3cc(O)ccc23)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 3/20 0.40
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
TLR8 Q9NR97 1/20 0.37
PIK3CD O00329 2/20 0.36
PIK3CA P42336 2/20 0.36
MAPK14 Q16539 5/20 0.36
GRIN2B Q13224 6/20 0.35
CSNK1E P49674 1/20 0.34
KCNH2 Q12809 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
GRIN1 Q05586 1/20 0.33
SERPINA2 P20848 1/20 0.33
PIK3CB P42338 1/20 0.33
MTOR P42345 1/20 0.33
ATR Q13535 1/20 0.33
ATRIP Q8WXE1 1/20 0.33
CSF1R P07333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25544357 0.90 PRKDC (0.39) PRKDCPDE3BPDE3AMAPK14GRIN2B
SCHEMBL23888028 0.83 TLR8 (0.39) PRKDCPDE3BPDE3ATLR8MAPK14
SCHEMBL25544752 0.79 MAPK14 (0.39) PRKDCPDE3BPDE3APIK3CAMAPK14
SCHEMBL23888050 0.75 GRIN2B (0.40) PRKDCTLR8GRIN2BKCNH2CYP1A2
SCHEMBL23887717 0.73 TLR8 (0.42) TLR8GRIN2BKCNH2CYP2C9CYP2C19
SCHEMBL30367763 0.73 TLR8 (0.42) TLR8GRIN2BKCNH2CYP2C9CYP2C19
SCHEMBL25544932 0.71 MAPK14 (0.36) PRKDCPDE3BPDE3AMAPK14CSNK1E
SCHEMBL23887884 0.70 GRM4 (0.38) MAPK14CSNK1E
SCHEMBL30367978 0.70 GRM4 (0.38) MAPK14CSNK1E
SCHEMBL30121044 0.67 NPC1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 PRKDC 4039/4885PDE3B 1105/4885PDE3A 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.